Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May-Jun;51(3):e70023.
doi: 10.1002/biof.70023.

The Immunotherapeutic Target ANLN Promotes Renal Clear Cell Carcinoma by Regulating PI3K/Akt and P53 Signaling Pathways

Li Shan  1   2 , Guo-Jian Gu  3 , Cheng-Cheng Xiang  2 , Er-Dong Zuo  2 , Lian Lian  1   4 , Xu Cheng  2
Affiliations

The Immunotherapeutic Target ANLN Promotes Renal Clear Cell Carcinoma by Regulating PI3K/Akt and P53 Signaling Pathways

Li Shan et al. Biofactors. 2025 May-Jun.

Abstract

The role of Anillin (ANLN) in clear cell renal cell carcinoma (ccRCC) is not well understood. This study aimed to investigate the possible function and mechanism of ANLN in ccRCC. By using data from the Cancer Genome Atlas (TCGA), we assessed ANLN expression in various cancers. Furthermore, the GEPIA database was used to analyze survival rates, pathway enrichment, and immune infiltration. Experiments were employed to study how ANLN expression affects tumor cell apoptosis, migration, invasion, and proliferation. Protein blotting was conducted to evaluate apoptosis, proliferation, epithelial mesenchymal transition (EMT), and the expression of proteins linked to the PI3K/AKT and P53 signaling pathways. mRNA levels of ANLN were notably increased in diverse cancer tissues, as shown in the TCGA database, a finding that was also observed in ccRCC patients. Remarkably, high ANLN levels were associated with lower pathologic grades and a worse survival prognosis in ccRCC patients. In vitro experiments revealed that knockdown of ANLN in ccRCC cells led to reduced proliferation, migration, invasion, and EMT. Additionally, ANLN seemed to impact immune evasion and increase the likelihood of distant metastasis based on immune infiltration analyses. The use of PI3K/AKT pathway inhibitors or P53 signaling pathway agonists was effective in reducing the invasive behavior of ccRCC and correcting immunosuppression. Overall, ANLN could be a valuable prognostic indicator for the survival of ccRCC patients.

Keywords: AKT kinase inhibitor; ANLN; KIRC; bioinformatics; immune signaling; immunotherapy.

PubMed Disclaimer

References

    1. U. Capitanio and F. Montorsi, “Renal Cancer,” Lancet 387, no. 10021 (2016): 894–906.
    1. U. Capitanio, K. Bensalah, A. Bex, et al., “Epidemiology of Renal Cell Carcinoma,” European Urology 75, no. 1 (2019): 74–84.
    1. H. Moch, A. L. Cubilla, P. A. Humphrey, V. E. Reuter, and T. M. Ulbright, “The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs‐Part A: Renal, Penile, and Testicular Tumours,” European Urology 70, no. 1 (2016): 93–105.
    1. B. Ljungberg, L. Albiges, Y. Abu‐Ghanem, et al., “European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update,” European Urology 82, no. 4 (2022): 399–410.
    1. P. C. Barata and B. I. Rini, “Treatment of Renal Cell Carcinoma: Current Status and Future Directions,” Cancer Journal for Clinicians 67, no. 6 (2017): 507–524.

MeSH terms

Substances

LinkOut - more resources